Inside the COINS Act: How Treasury’s China Rule Could Reshape Drug Development
Could Treasury’s proposed COINS Act rule make it harder for American patients to get promising new medicines?
The proposed regulations would restrict a broad range of transactions with Chinese companies. That could change how U.S. biotech companies partner, invest, and bring new therapies to American patients. But how far does the rule actually reach?
In this Making Medicine Press Pass episode, host John Stanford welcomes Max Bayer, Senior Reporter at Endpoints News, to break down Treasury’s proposed COINS Act rule and what it could mean for drug development in the United States.
Max shares…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.